摘要
目的探究拉莫三嗪联合丙戊酸钠对双相障碍抑郁发作患者的甲状腺功能、脑源性神经营养因子(BDNF)和C反应蛋白(CRP)的影响。方法选取2021年4月至2023年4月就诊的双相障碍抑郁发作患者100例,随机分为对照组和观察组各50例。对照组采用丙戊酸钠治疗,观察组采用拉莫三嗪联合丙戊酸钠治疗。比较2组临床疗效、汉密尔顿抑郁量表-24(HAMD-24)评分、甲状腺功能相关指标、BDNF、CRP和不良反应发生情况。结果观察组总有效率高于对照组,差异有统计学意义(P<0.05);观察组HAMD-24评分和促甲状腺激素(TSH)水平低于对照组(P<0.05),三碘甲状腺原氨酸(T_(3))和甲状腺素(T_(4))水平高于对照组(P<0.05);观察组BDNF水平高于对照组,CRP水平低于对照组(P<0.05);2组不良反应总发生率比较差异无统计学意义(P>0.05)。结论拉莫三嗪联合丙戊酸钠治疗双相障碍抑郁发作患者,可提高治疗总有效率,改善临床症状,保护甲状腺功能,提高BDNF水平,降低CRP水平,值得临床推广。
AIM To explore the effects of lamotrigine and sodium valproate on thyroid hormone,brain-derived neurotrophic factor(BDNF)and C-reactive protein(CRP)in patients with depressive episodes of bipolar disorder.METHODS According to the inclusion and exclusion criteria,100 patients with bipolar depressive episodes from April 2021 to April 2023 were selected and randomly divided into control group and observation group,with 50 patients in each group.The control group was treated with sodium valproate,and the observation group was treated with lamotrigine combined with sodium valproate.The clinical efficacy,Hamilton rating scale for depression(HAMD-24)score,BDNF level,CRP level,thyroid hormone levels and adverse reactions of 2 groups were observed and compared.RESULT After treatment,the total effective rate of observation group was significantly higher than that of control group(P<0.05).After treatment,compared with the control group,the HAMD-24 score and TSH value were lower in the observation group,and the T_(3) and T_(4) values were higher(P<0.05).Compared with the control group,after treatment,the level of BDNF in the observation group was higher and the level of CRP was lower(P<0.05).After treatment,there was no significant difference in the total incidence of adverse reactions between 2 groups(P>0.05).CONCLUSION Combination of lamotrigine with sodium valproate in patients with depressive episodes of bipolar disorder improves treatment adherence,improves clinical symptoms,promotes a rise in thyroid hormone and BDNF levels,and decreases CRP level,which is worthy of clinical promotion.
作者
戴边
杨致蓉
刘冰
DAI Bian;YANG Zhirong;LIU Bing(Medical Services Department,The Second Hospital of Jinhua,Jinhua 321016,China;Department of Psychiatry,The Second Hospital of Jinhua,Jinhua 321016,China)
出处
《中国临床药学杂志》
CAS
2024年第7期525-528,共4页
Chinese Journal of Clinical Pharmacy
关键词
拉莫三嗪
丙戊酸钠
双相障碍
抑郁
甲状腺激素
C反应蛋白
脑源性神经营养因子
lamotrigine
sodium valproate
bipolar disorder
depression
thyroid hormone
C-reactive protein
brain-derived neurotrophic factor
